Insights - The FDA granted Pfizer and partner BioNTech full approval for their vaccine last week. Meanwhile, there were reports from Reuters that Novavax (NVAX) may face additional delays … Continue Reading
Premium: Read NowInsights - Biotech got a jolt of life after Pfizer announced the $2.26B acquisition of Trillium (TRIL), at a 204% premium to market close on Friday. The … Continue Reading
Premium: Read NowInsights - Fate Therapeutics (FATE) reported additional data for their two off-the-shelf NK cell programs after market yesterday. This was an important event because it would read-through to NK … Continue Reading
Premium: Read NowInsights - Eloxx (ELOX) provided a Q2 business update earlier this week, and everything was on schedule. Based on enrollment at the end of June, the company remainson track to report … Continue Reading
Premium: Read NowInsights - Essa (EPIX) reported their Q2 business update this morning. The rumors were true – Phase 1 monotherapy data will be pushed from 2H 2021 to 1H 2022. … Continue Reading
Premium: Read NowInsights - Essa (EPIX) is down 50% in the last month, with really aggressive selling coming in the last 6 trading days. Since Thursday August 5th, Essa … Continue Reading
Premium: Read NowInsights - Novavax (NVAX) had their Q2 business update call yesterday after market. The company announced yet another delay in the US submission, while the rest of the world’s … Continue Reading
Premium: Read Now
